The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes

Cancer Research

Volumn 62, Issue 4, 2002, Pages 1077-1082

  Carlomagno, Francesca ^a   Vitagliano, Donata ^a   Guida, Teresa ^a   Vecchio, Giancarlo ^a   Fusco, Alfredo ^a   Santoro, Massimo ^a   Gazit, Aviv ^b   Levitzki, Alexander ^b   Napolitano, Maria ^c  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; AG 213; AG 555; AG 82; AGL 2137; AGL 2164; AGL 2174; AGL 2189; CINNAMOMALONITRILE; N (4 BUTYLPHENYL) ALPHA CYANOCAFFEIC ACID AMIDE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLOPYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE RET; PRIORITY JOURNAL; THYROID PAPILLARY CARCINOMA;

3T3 CELLS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DROSOPHILA PROTEINS; ENZYME INHIBITORS; GENE EXPRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MICE; MICE, INBRED BALB C; ONCOGENES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; PYRAZOLES; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0036171234     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. The RET proto-oncogene in human cancers
2. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
3. Molecular characterization of RET/PTC3; a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma
4. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas
5. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children
6. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line
7. The RET/PTC3 oncogene: Metastatic solid-type papillary carcinomas in murine thyroids
8. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
9. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma
10. The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome
11. Prognostic value of codon 918 (ATG>ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma
12. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B
13. The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane
14. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling
15. Protein tyrosine kinase inhibitors as novel therapeutic agents
16. Tyrosine kinase inhibition: An approach to drug development
17. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors
18. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
19. Anticancer drug targets: Growth factors and growth factor signaling
20. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
21. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling
22. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes
23. cDNA cloning and characterization of ret activated in a human papillary thyroid carcinoma cell line
24. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas
25. An epidermal growth factor receptor/ret chimera generates mitogenic and transforming signals: Evidence for a ret-specific signaling pathway
26. Activity-dependent interaction of the intracellular domain of rat trkA with intermediate filament proteins, the β-6 proteasomal subunit, Ras-GRF1, and the p162 subunit of eIF3
27. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation
28. Shc and Enigma are both required for mitogenic signaling by Ret/ptc2
29. Docking protein frs2 links the protein tyrosine kinase ret and its oncogenic forms with the mitogen-activated protein kinase signaling cascade
30. Ret-mediated mitogenesis requires Src kinase activity
31. Signal-transduction therapy. A novel approach to disease management
32. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
33. A dual inhibitor of platelet-derived growth factor β-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling
34. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor
35. A chemical switch for inhibitor-sensitive alleles of any protein kinase
36. Inhibition of transforming activity of the ret/ptc1 oncoprotein by a 2-indolinone derivative